Invesco Pharmaceuticals ETF

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

Report claims Trump purchased Eli Lilly stock during period of favorable government policies

Investment firm GLOBALT increases its stake in Eli Lilly and Company

Multiple analyst firms update ratings and earnings forecasts for Eli Lilly

Eli Lilly's Q1 2026 revenue soars 56%, topping global pharmaceutical sales charts

Nanobiotix Reports 85.7% Response Rate for JNJ-1900 in Lung Cancer Trial Phase II

Amesite

InMed Pharmaceuticals

Meiwu Tech

Co-Diagnostics

Phoenix Asia

MetaVia

Rubico

Generation Income Properties

Virax Biolabs

Hub Cyber Security

WGRX

Wellgistics Health Inc. will release its Q1 2026 earnings on May 19, 2026, after market close. The update will provide insights into the performance of its AI-driven pharmacy platform and blockchain distribution model, which connects over 6,500 pharmacies with 200 manufacturers. This earnings report is anticipated to influence investor perceptions regarding the company's competitive position and growth potential in the healthcare sector.

Tip Ranks

Wellgistics Health

iShares US Pharma

VanEck Pharmaceutical ETF

SPDR Pharmac

Wellgistics Health Schedules First-Quarter 2026 Earnings Release

Cardinal Health Inc. (CAH) shares rose 2.34% to $199.77 on a mixed trading day, marking its fifth consecutive gain. The stock remains 14.48% below its 52-week high of $233.60. Competitors had varied performances, with Amazon up 0.27%, UnitedHealth down 0.69%, and CVS up 0.10%. Trading volume reached 2.4 million, surpassing the 50-day average of 2.0 million.

MarketWatch Automated

Cardinal Health

SPDR S&P Health Equip

iShares US Medical Devices

Dow Jones Industrial Average

S&P 500

Amazon

Unitedhealth

CVS Health

Cardinal Health Inc. Stock Outperforms Competitors On Strong Trading Day

LABU

McKesson (MCK) reported strong Q4 and full year earnings, with increased sales and net income, leading to a 1.79% rise in stock price to $760.57. Despite recent declines, long-term returns remain robust. Analysts suggest the stock is undervalued at $951.73, driven by earnings power and acquisitions. However, a DCF model indicates potential downside risk, emphasizing the need to weigh earnings against cash generation. Investors are encouraged to explore other opportunities in healthcare.

Simplywall

McKesson

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Assessing McKesson (MCK) Valuation After Strong Q4 And Full Year Earnings Results

Cencora's fiscal Q2 2026 results revealed higher sales of $78.36 billion and net income of $1.64 billion, but a revenue miss and lowered growth outlook have raised concerns about its margin expansion narrative. The company confirmed a 4% to 6% revenue growth guidance for 2026, but ongoing investigations and pricing pressures could impact margins. Analysts are cautious, with some projecting only 4.5% annual growth. Cencora's future performance will be critical in restoring investor confidence and shaping its stock sentiment.

Cencora

Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative?

Pomerantz Law Firm is investigating claims for investors of Cencora, Inc. (NYSE: COR) regarding potential securities fraud by the company and its officers. Following Cencora's Q2 2026 results, which missed revenue estimates and lowered growth guidance, the stock price dropped 17.4%. Investors are encouraged to contact Pomerantz for more information.

prnewswire

22:25 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

Cencora Inc. (COR) shares rose 2.12% to $261.11 on a strong trading day, outperforming competitors like Amazon, UnitedHealth, and CVS. The S&P 500 and Dow Jones also saw gains of 0.77% and 0.75%, respectively. Despite the increase, Cencora remains 30.84% below its 52-week high of $377.54 reached on November 25. Trading volume was significantly higher than its 50-day average.

Factset Research

Cencora Inc. Stock Outperforms Competitors On Strong Trading Day

McKesson Corp. (MCK) shares rose 1.36% to $747.23 on a positive trading day, outperforming competitors like Amazon, UnitedHealth, and CVS. This marks the third consecutive day of gains for McKesson, although it remains 25.20% below its 52-week high of $999.00 reached on March 3rd. The trading volume was 921,594, surpassing the 50-day average of 909,974.

McKesson Corp. Stock Outperforms Competitors On Strong Trading Day

NXPL

NextPlat (NASDAQ:NXPL) reported its Q1 2026 financial results, highlighting significant margin expansion and improved profitability, primarily from its healthcare operations, which contributed 68% of revenue. The company regained compliance with NASDAQ's minimum bid requirement after a reverse stock split. Gross margin increased to 35% from 21% year-over-year, driven by higher-margin revenue streams. NextPlat ended the quarter with $11 million in cash and no significant debt, focusing on sustaining profitability and exploring growth through potential joint ventures or acquisitions.

benzinga_article

NextPlat

VG Health

SPDR S&P Health

Health Care Select Sector SPDR

NEXTPLAT CORP C/WTS 02/06/2026 (TO PUR COM)

NextPlat Reports Q1 2026 Results: Full Earnings Call Transcript

NextPlat Corp reported $9.9 million in revenue for Q1 2026, a 29% decrease from the previous year, primarily due to lower healthcare revenue. However, the company achieved a record gross margin of 35%, up from 21% year-over-year, driven by improved pharmacy operations and new contracts. Operating expenses decreased by 9% to $4.5 million, reflecting ongoing cost-cutting measures. The CEO expressed optimism about future growth and profitability, anticipating positive income from operations in the latter half of 2026 as the company continues its turnaround efforts.

08:01 ETNextPlat Reports $9.9 Million in Revenue for Q1 2026 with Record Quarterly Consolidated Gross Margins of 35%

510660

ARKG

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Invesco Pharmaceuticals ETF(PJP.US)